Vaping should be ‘promoted’ as smoking cessation aid

Vaping should be ‘promoted’ as smoking cessation aid

October 17 2017 Electronic cigarettes should be promoted as a method of stopping smoking, the...

MHRA issues Drug Safety Updates for loperamide and miconazole

MHRA issues Drug Safety Updates for loperamide and miconazole

October 4 2017 The medicines regulator, the MHRA, has issued Drug Safety Updates on two...

Leo withdraws plans to launch OTC version of Dovonex

Leo withdraws plans to launch OTC version of Dovonex

September 20 2017 Leo Pharma has announced it will not now launch an over-the-counter version of...

Boots introduces generic levonorgestrel for EHC service

Boots introduces generic levonorgestrel for EHC service

September 4 2017 Boots has announced it is starting to make available a cheaper generic...

Which? challenges effectiveness, variety and cost of branded OTC medicines

Which? challenges effectiveness, variety and cost of branded OTC medicines

August 29 2017 Which? has published an article questioning the effectiveness of some over the...

  • Vaping should be ‘promoted’ as smoking cessation aid

    Vaping should be ‘promoted’ as smoking cessation aid

    Tuesday, 17 October 2017 14:31
  • MHRA issues Drug Safety Updates for loperamide and miconazole

    MHRA issues Drug Safety Updates for loperamide and miconazole

    Wednesday, 04 October 2017 16:25
  • Leo withdraws plans to launch OTC version of Dovonex

    Leo withdraws plans to launch OTC version of Dovonex

    Wednesday, 20 September 2017 14:11
  • Boots introduces generic levonorgestrel for EHC service

    Boots introduces generic levonorgestrel for EHC service

    Monday, 04 September 2017 15:09
  • Which? challenges effectiveness, variety and cost of branded OTC medicines

    Which? challenges effectiveness, variety and cost of branded OTC medicines

    Tuesday, 29 August 2017 15:16

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

ApprovalJune 22 2016

The All Wales Medicines Strategy Group has announced two new recommendations for medicines by the NHS in Wales. The Scottish Medicines Consortium has recommended four medicines for use, but has also advised against two others.

The AWSMG recommendations are:

  • pasireotide (Signifor) for treating adults with acromegaly when surgery is not an option or has not been curative and when other somatostatin analogues are not adequately controlling the condition;
  • dulaglutide (Trulicity) for restricted use in type 2 diabetes in adults to improve glycaemic control where there has been a failure, intolerance or a contraindication to standard triple therapy (metformin and two other antidiabetic medicines) as an alternative to insulin therapy. It can also be used in combination with other glucose-lowering medicinal products but not insulin, when these, together with diet and exercise, have not provided adequate glycaemic control.

In Scotland, the SMC approvals are for:

  • co-careldopa (Duodopa) for advanced Parkinson’s disease and administered as a gel directly into the small intesting via a pump and tubing surgically inserted into the gut;
  • mepolizumab (Nucala) for severe eosinophilic asthma
  • blinatumomab (Blincyto) for acute lymphoblastic leukaemia
  • febuxostat (Adenuric) for patients at risk of Tumour Lysis Syndrome (TLS), a complication due to the breakdown of cancer cells leading to a rise in uric acid level in the blood which can then cause kidney damage

The Committee was unable to accept cabazitaxel (Jevtana) for advanced prostate cancer and evolocumab (Repatha) for high cholesterol.

Asthma UK has welcomed the SMC decision on mepolizumab, but remains concerned that NICE is proposing not to recommend the drug for use in England. Dr Samantha Walker, Asthma UK's Director of Research and Policy, said:

“Whilst Asthma UK has worked very hard to make sure that use of this crucial treatment for people with severe asthma was accepted in Scotland, which we are delighted to see, we have grave concerns over the difference in the situation in England.

“Mepolizumab has been shown to be clinically effective at reducing severe asthma symptoms in people with a certain type of asthma and should be available to those people who are most likely to benefit from it. Obviously this needs to be at a price that the NHS can afford, so it is essential that NICE and the manufacturer continue to work together and find a solution.”

Links:

AWSMG decisions

SMC announcement

Asthma UK comment

OTC News

October 20 2017 The Royal Pharmaceutical Society is calling for the government to provide pharmacists with state-backed indemnity cover, along the lines being proposed for GPs.
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...